Study Examines Statin Therapy Benefits Across Age Groups

Overview of Statin Therapy

A recent study has evaluated the effectiveness of statin therapy in reducing cardiovascular events across various age demographics, specifically including individuals aged 75 and older. Statins are widely prescribed medications that lower cholesterol levels and are typically given to patients at risk of significant cardiovascular incidents, such as heart attacks and strokes.

Research Background

While substantial evidence supports the efficacy of statins in decreasing the risk of cardiovascular events in diverse populations, findings concerning older adults, particularly those over 75, remain less definitive. The Cholesterol Treatment Trialists’ Collaboration conducted a meta-analysis of 28 statin therapy trials, which was published in The Lancet. In this study, participants were categorized into six age brackets: 55 years or younger, 56 to 60 years, 61 to 65 years, 66 to 70 years, 71 to 75 years, and those older than 75. The median follow-up period across all trials was 4.9 years.

Impact on Cardiovascular Event Risk

The analysis revealed that statin therapy lowered the overall risk of cardiovascular events by 21% for every 1 mmol/L decrease in LDL cholesterol levels. This risk reduction was consistent and significant across all age groups, including those aged over 75. Specifically, the risk reduction for coronary events was noted to be 24% for each 1 mmol/L reduction in LDL cholesterol, although it slightly diminished with advancing age. Moreover, the risk of death related to vascular issues decreased by 12% per 1 mmol/L reduction in LDL cholesterol due to statin therapy, with no significant effect observed on deaths from non-vascular causes or cancer. When evaluating all causes of mortality, a notable risk reduction associated with statin therapy was identified.

Primary vs. Secondary Prevention

The meta-analysis also differentiated between the benefits of statin therapy in primary prevention (patients without a history of vascular disease) and secondary prevention (patients with a history of vascular disease). Strong evidence supports the advantages of statin therapy in secondary prevention. However, the evidence for primary prevention remains less robust, largely due to fewer older participants in the related trials. The combined analysis of both prevention strategies indicated comparable proportional reductions in vascular-related deaths across all age brackets.

Conclusion on Statin Therapy Risks and Benefits

Researchers assert that the benefits of statin therapy considerably outweigh the associated risks, which may include muscle aches. They conclude that statin therapy significantly reduces the incidence of vascular events across all ages. Despite the limited direct evidence in patients aged 75 and older, the findings support the continued use of statins in older individuals who are at high risk for cardiovascular events.

References

Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., . . . Zannad, F. (2019). Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet, 393(10170), 407-415. doi:10.1016/s0140-6736(18)31942-1
The Lancet: Statin therapy reduces risk of major cardiovascular events irrespective of age. (2019, January 31). Retrieved from https://www.eurekalert.org/pub_releases/2019-01/tl-tls013019.php